Company: IXHL
Filing Date: 2025-03-24
Form Type: S-3
Source: 0001013762-25-001587
Chunk: 14

Company: Incannex Healthcare Inc.
Filing Date: 2025-03-24
Form: S-3
Chunk 14
---
 the year ended June 30, 2024 filed with the SEC on September 30, 2024, as updated by our subsequent filings with the SEC under the Exchange Act, which are incorporated by reference, in this prospectus, and any updates to those risk factors included from time to time in our periodic and current reports filed with the SEC and incorporated by reference in this prospectus, before making any decision to invest in shares of our Common Stock. If any of the events discussed in these risk factors occurs, our business, prospects, results of operations, financial condition and cash flows could be materially harmed. If that were to happen, the trading price of our Common Stock could decline, and you could lose all or part of your investment. Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.

<div align='center'>6

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</div>

This prospectus, including
documents incorporated by reference herein and therein, and any free writing prospectus that we have authorized for use in connection
with this offering, contain forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the
Exchange Act. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or our
future performance, and they are based on our current assumptions, expectations and beliefs concerning future developments and their potential
effect on our business. The words “believe,” “may,” “will,” “potentially,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “would,” “project,”
“plan,” “expect,” “possible,” “likely,” “probable,” and similar expressions
that convey uncertainty of future events or outcomes identify forward-looking statements. These statements include, among other things,
statements regarding:

| · | our ability to implement                                                                                                                    
 our product development and business strategies, including our ability to continue to pursue development pathways and regulatory strategies 
 for IHL-42X, PSX-001, and IHL-675A and any of our other drug candidates;                                                                    |

| · | estimates regarding                          
 market size and related future growth rates; |

| · | our research and development activities, including clinical 
 testing and manufacturing and the related costs and timing; |

| · | the possibility that we may be required to conduct additional                                                                                 
 clinical studies or trials for our drug